<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172780</url>
  </required_header>
  <id_info>
    <org_study_id>MYL-1601N-3002</org_study_id>
    <nct_id>NCT03172780</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study Using Clinical Endpoint for Diclofenac Sodium Gel 1% in Osteoarthritis Knee&quot;</brief_title>
  <official_title>A Randomized, Double Blind, Three-arm, Parallel, Placebocontrolled, Clinical Study to Evaluate the Bioequivalence Using Clinical Endpoint of Diclofenac Sodium Gel, 1% (Mylan Inc.) to Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis Consumer Health, Inc.) in Patients With Osteoarthritis (OA) of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mylan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind, three-arm, placebo controlled, bioequivalence study with&#xD;
      clinical endpoint has been designed to establish clinical equivalence and safety of Mylan's&#xD;
      diclofenac gel in the symptomatic treatment of osteoarthritis of knee compared to Voltaren®&#xD;
      gel and to establish superiority in efficacy of both compared to a placebo (vehicle) gel.&#xD;
&#xD;
      Male or non-pregnant female aged ≥ 35 years with a clinical diagnosis of osteoarthritis of&#xD;
      the knee according to the American College of Rheumatology (ACR) criteria&#xD;
&#xD;
      Total study duration for the clinical part will be around 56 days that includes screening&#xD;
      period of 28 days and treatment period of 4 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 24, 2017</start_date>
  <completion_date type="Actual">December 5, 2017</completion_date>
  <primary_completion_date type="Actual">December 5, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in the Total WOMAC Pain Subscale Score</measure>
    <time_frame>From baseline to week 4</time_frame>
    <description>Mean change in the total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain subscale score for the target knee was compared to determine the clinical equivalence of Test Drug (Diclofenac sodium gel of 1% of Mylan Inc.) with the Reference Listed Drug (RLD) (Voltaren® Gel 1% of Novartis Consumer Health, Inc.) Measure Description: Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale score (pain score = min 0 to max 20), was determined by the sum of subject's responses to five questions (S1-S5) using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4). Higher values represent worse outcome.&#xD;
'How much pain do you have' when 'Walking on a flat surface' (S1), 'Going up or down stairs' (S2), 'at night while in bed' (S3), 'Sitting or lying' (S4), 'Standing upright' (S5)].&#xD;
The timepoints considered for the primary outcomes include baseline and week 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in WOMAC Pain Subscale Score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Mean change in the total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain subscale score for the target knee was compared to determine the superiority of the Test Drug and Reference Listed Drug (RLD) over placebo.&#xD;
Measure Description: Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale score (pain score = min 0 to max 20), was determined by the sum of subject's responses to five questions (S1-S5) using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4). Higher values represent worse outcome.&#xD;
'How much pain do you have' when 'Walking on a flat surface' (S1), 'Going up or down stairs' (S2), 'at night while in bed' (S3), 'Sitting or lying' (S4), 'Standing upright' (S5)].&#xD;
The timepoints considered for the primary outcomes include baseline and week 4.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1220</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Diclofenac Sodium Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diclofenac Sodium Gel, 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Voltaren® Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac sodium gel 1%</intervention_name>
    <description>Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks</description>
    <arm_group_label>Diclofenac Sodium Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%</intervention_name>
    <description>Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks</description>
    <arm_group_label>Voltaren® Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo gel</intervention_name>
    <description>Vehicle Gel 4 gm, 4 times a day for 4 weeks</description>
    <arm_group_label>Placebo gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Osteoarthritis knee as per American College of Rheumatology (ACR) criteria&#xD;
&#xD;
          -  Evidence of OA with Kellgren-Lawrence grade 1-3 disease.&#xD;
&#xD;
          -  After discontinuing all pain medications, had at least moderate pain on movement (POM)&#xD;
             for target knee&#xD;
&#xD;
          -  After discontinuing all pain medications for at least 7 days has a baseline Western&#xD;
             Ontario and McMaster Universities Osteoarthritis Index (WOMAC Likert (version 3.1))&#xD;
             pain subscale of ≥ 9 immediately prior to randomization.&#xD;
&#xD;
          -  Able to tolerate rescue medication with acetaminophen&#xD;
&#xD;
          -  Subjects who can read and understand WOMAC pain sub scale&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, lactation&#xD;
&#xD;
          -  OA of Kellgren-Lawrence grade 4&#xD;
&#xD;
          -  OA pain in the contralateral knee requiring medication (OTC or prescription)&#xD;
&#xD;
          -  History of OA of either Hip or Hands&#xD;
&#xD;
          -  History of secondary OA (e.g. congenital, traumatic, gouty arthritis), rheumatoid&#xD;
             arthritis&#xD;
&#xD;
          -  History of chronic inflammatory disease (e.g., colitis) or fibromyalgia&#xD;
&#xD;
          -  History of Drugs or Alcohol abuse within the previous year&#xD;
&#xD;
          -  Symptomatic peripheral vascular disease of the study leg&#xD;
&#xD;
          -  Any musculoskeletal condition&#xD;
&#xD;
          -  Skin disease at the application site&#xD;
&#xD;
          -  Active asthma requiring periodic treatment with systemic steroids&#xD;
&#xD;
          -  Known history of positive HIV, hepatitis C virus, or HBsAg&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  History of myocardial infarction, thrombotic events, stroke etc.&#xD;
&#xD;
          -  Allergy to aspirin, nonsteroidal anti-inflammatory drugs (NSAID) or acetaminophen&#xD;
             (paracetamol).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yashoda Hospital - Malakpet</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500036</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yashoda Hospital -Secunderabad</name>
      <address>
        <city>Secunderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yashoda Hospital -Somajiguda</name>
      <address>
        <city>Somajiguda</city>
        <state>Andhra Pradesh</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King George Hospital</name>
      <address>
        <city>Visakhapatnam</city>
        <state>Andhra Pradesh</state>
        <zip>530002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riddhi Medical Nursing Home</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rathi Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanjivani Superspeciality Hospital Pvt. Ltd</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>B.J Medical College &amp; Civil Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GMERS Medical College &amp; Civil Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380061</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SSG Hospital and Medical College</name>
      <address>
        <city>Baroda</city>
        <state>Gujarat</state>
        <zip>39000</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medistar Multispeciality Hospital</name>
      <address>
        <city>Himmatnagar</city>
        <state>Gujarat</state>
        <zip>383001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shree Giriraj Multispeciality Hospital</name>
      <address>
        <city>Rajkot</city>
        <state>Gujarat</state>
        <zip>360005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anand Multispeciality Hospital</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parul Sevashram Hospital</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>391760</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Hospital</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>575002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mysore Medical College and Research Institute</name>
      <address>
        <city>Mysore</city>
        <state>Karnataka</state>
        <zip>570001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sree Narayana Institute of Medical Science</name>
      <address>
        <city>Ernakulam</city>
        <state>Kerala</state>
        <zip>683594</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir J. J. Group of Hospital and Grant Government Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lokmanya Tilak Municipal Medical College &amp; General Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Government Medical College and Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jasleen Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Medical sciences and Lata Mangeshkar</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>600001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Supe Heart and Diabetes Hospital &amp; Research Centre</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BJ medical college &amp; Sassoon General Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sancheti Institute for Orthopedics &amp; Rehabilitation</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BhaktiVedanta Hospital and Research Institute</name>
      <address>
        <city>Thane</city>
        <state>Maharashtra</state>
        <zip>401107</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMS and SUM Hospital</name>
      <address>
        <city>Bhubaneshwar</city>
        <state>Odisha</state>
        <zip>751003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Govt Stanley Medical College &amp; Hospital</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.V. Hospital &amp; Research Centre</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajanta Research Centre</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OM surgical Centre and Maternity Home</name>
      <address>
        <city>Varanasi</city>
        <state>Uttar Pradesh</state>
        <zip>221007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Post Graduate Medical Education and Research (IPGMER), Department of Orthopaedics</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>May 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <results_first_submitted>January 13, 2021</results_first_submitted>
  <results_first_submitted_qc>March 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 20, 2021</results_first_posted>
  <disposition_first_submitted>July 20, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 25, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 20, 2021</disposition_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 6, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT03172780/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT03172780/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diclofenac Sodium Gel</title>
          <description>Diclofenac Sodium Gel, 1%&#xD;
Diclofenac sodium gel 1%: Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Voltaren® Gel</title>
          <description>Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%&#xD;
Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%: Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo Gel</title>
          <description>Placebo gel&#xD;
Placebo gel: Vehicle Gel 4 gm, 4 times a day for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="406"/>
                <participants group_id="P2" count="409"/>
                <participants group_id="P3" count="405"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="388"/>
                <participants group_id="P2" count="389"/>
                <participants group_id="P3" count="389"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diclofenac Sodium Gel</title>
          <description>Diclofenac Sodium Gel, 1%&#xD;
Diclofenac sodium gel 1%: Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Voltaren® Gel</title>
          <description>Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%&#xD;
Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%: Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo Gel</title>
          <description>Placebo gel&#xD;
Placebo gel: Vehicle Gel 4 gm, 4 times a day for 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="406"/>
            <count group_id="B2" value="409"/>
            <count group_id="B3" value="405"/>
            <count group_id="B4" value="1220"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" spread="9.51"/>
                    <measurement group_id="B2" value="53.4" spread="9.40"/>
                    <measurement group_id="B3" value="53.6" spread="10.15"/>
                    <measurement group_id="B4" value="53.4" spread="9.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="275"/>
                    <measurement group_id="B2" value="288"/>
                    <measurement group_id="B3" value="273"/>
                    <measurement group_id="B4" value="836"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="132"/>
                    <measurement group_id="B4" value="384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian/Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="406"/>
                    <measurement group_id="B2" value="409"/>
                    <measurement group_id="B3" value="405"/>
                    <measurement group_id="B4" value="1220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="406"/>
                    <measurement group_id="B2" value="409"/>
                    <measurement group_id="B3" value="405"/>
                    <measurement group_id="B4" value="1220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>WOMAC Pain subscale score for target knee</title>
          <description>Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale score (pain score = minimum 0 to maximum 20), was determined by the sum of subject's responses to five questions (S1-S5) using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4). Higher values represent worse outcome.&#xD;
'How much pain do you have' when 'Walking on a flat surface' (S1), 'Going up or down stairs' (S2), 'at night while in bed' (S3), 'Sitting or lying' (S4), 'Standing upright' (S5)].</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.4" spread="2.15"/>
                    <measurement group_id="B2" value="12.5" spread="2.16"/>
                    <measurement group_id="B3" value="12.4" spread="2.05"/>
                    <measurement group_id="B4" value="12.4" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in the Total WOMAC Pain Subscale Score</title>
        <description>Mean change in the total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain subscale score for the target knee was compared to determine the clinical equivalence of Test Drug (Diclofenac sodium gel of 1% of Mylan Inc.) with the Reference Listed Drug (RLD) (Voltaren® Gel 1% of Novartis Consumer Health, Inc.) Measure Description: Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale score (pain score = min 0 to max 20), was determined by the sum of subject's responses to five questions (S1-S5) using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4). Higher values represent worse outcome.&#xD;
'How much pain do you have' when 'Walking on a flat surface' (S1), 'Going up or down stairs' (S2), 'at night while in bed' (S3), 'Sitting or lying' (S4), 'Standing upright' (S5)].&#xD;
The timepoints considered for the primary outcomes include baseline and week 4.</description>
        <time_frame>From baseline to week 4</time_frame>
        <population>The PP Population was used for analysis of clinical equivalence between Mylan's Diclofenac gel and Voltaren gel. The primary outcome tested in this population was the equivalence of Mylan's Diclofenac sodium gel (1%) verses the Voltaren gel (1%) and thus only Diclofenac Sodium Gel and Voltaren Gel arms are present here. The placebo arm is presented for the superiority analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Diclofenac Sodium Gel</title>
            <description>Diclofenac Sodium Gel, 1%&#xD;
Diclofenac sodium gel 1%: Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Voltaren® Gel</title>
            <description>Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%&#xD;
Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%: Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in the Total WOMAC Pain Subscale Score</title>
          <description>Mean change in the total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain subscale score for the target knee was compared to determine the clinical equivalence of Test Drug (Diclofenac sodium gel of 1% of Mylan Inc.) with the Reference Listed Drug (RLD) (Voltaren® Gel 1% of Novartis Consumer Health, Inc.) Measure Description: Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale score (pain score = min 0 to max 20), was determined by the sum of subject's responses to five questions (S1-S5) using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4). Higher values represent worse outcome.&#xD;
'How much pain do you have' when 'Walking on a flat surface' (S1), 'Going up or down stairs' (S2), 'at night while in bed' (S3), 'Sitting or lying' (S4), 'Standing upright' (S5)].&#xD;
The timepoints considered for the primary outcomes include baseline and week 4.</description>
          <population>The PP Population was used for analysis of clinical equivalence between Mylan's Diclofenac gel and Voltaren gel. The primary outcome tested in this population was the equivalence of Mylan's Diclofenac sodium gel (1%) verses the Voltaren gel (1%) and thus only Diclofenac Sodium Gel and Voltaren Gel arms are present here. The placebo arm is presented for the superiority analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="2.64"/>
                    <measurement group_id="O2" value="-4.6" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in WOMAC Pain Subscale Score</title>
        <description>Mean change in the total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain subscale score for the target knee was compared to determine the superiority of the Test Drug and Reference Listed Drug (RLD) over placebo.&#xD;
Measure Description: Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale score (pain score = min 0 to max 20), was determined by the sum of subject's responses to five questions (S1-S5) using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4). Higher values represent worse outcome.&#xD;
'How much pain do you have' when 'Walking on a flat surface' (S1), 'Going up or down stairs' (S2), 'at night while in bed' (S3), 'Sitting or lying' (S4), 'Standing upright' (S5)].&#xD;
The timepoints considered for the primary outcomes include baseline and week 4.</description>
        <time_frame>4 weeks</time_frame>
        <population>The mITT Population was used for analysis of superiority of Mylan's Diclofenac gel and Voltaren gel over placebo. The primary outcome tested in this population was the superiority of Mylan's Diclofenac sodium gel (1%) and the Voltaren gel (1%) over placebo and thus all the three arms are presented here.</population>
        <group_list>
          <group group_id="O1">
            <title>Diclofenac Sodium Gel</title>
            <description>Diclofenac Sodium Gel, 1%&#xD;
Diclofenac sodium gel 1%: Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Voltaren® Gel</title>
            <description>Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%&#xD;
Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%: Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo Gel</title>
            <description>Placebo gel&#xD;
Placebo gel: Vehicle Gel 4 gm, 4 times a day for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WOMAC Pain Subscale Score</title>
          <description>Mean change in the total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain subscale score for the target knee was compared to determine the superiority of the Test Drug and Reference Listed Drug (RLD) over placebo.&#xD;
Measure Description: Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale score (pain score = min 0 to max 20), was determined by the sum of subject's responses to five questions (S1-S5) using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4). Higher values represent worse outcome.&#xD;
'How much pain do you have' when 'Walking on a flat surface' (S1), 'Going up or down stairs' (S2), 'at night while in bed' (S3), 'Sitting or lying' (S4), 'Standing upright' (S5)].&#xD;
The timepoints considered for the primary outcomes include baseline and week 4.</description>
          <population>The mITT Population was used for analysis of superiority of Mylan's Diclofenac gel and Voltaren gel over placebo. The primary outcome tested in this population was the superiority of Mylan's Diclofenac sodium gel (1%) and the Voltaren gel (1%) over placebo and thus all the three arms are presented here.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
                <count group_id="O2" value="402"/>
                <count group_id="O3" value="396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="2.84"/>
                    <measurement group_id="O2" value="-4.4" spread="2.74"/>
                    <measurement group_id="O3" value="-3.2" spread="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The reporting period for TEAEs started after the informed consent through day 28 after the last application of investigational product, a total of approximately 12 weeks.</time_frame>
      <desc>The safety analysis was performed based on safety population that includes all patients who were treated with at least one application of the investigational product. The total number of patients included in this population were 1203 (398 for Mylan's Diclofenac gel, 405 for Voltaren gel and 400 for placebo).</desc>
      <group_list>
        <group group_id="E1">
          <title>Diclofenac Sodium Gel</title>
          <description>Diclofenac Sodium Gel, 1%&#xD;
Diclofenac sodium gel 1%: Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Voltaren® Gel</title>
          <description>Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%&#xD;
Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%: Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo Gel</title>
          <description>Placebo gel&#xD;
Placebo gel: Vehicle Gel 4 gm, 4 times a day for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="405"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="398"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="405"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="398"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="405"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Prasanna C Ganapathi, Associate Vice President, Global Clinical Sciences</name_or_title>
      <organization>Mylan Pharmaceuticals Pvt Ltd.</organization>
      <phone>08066728952 ext 28952</phone>
      <email>PrasannaC.Ganapathi@mylan.in</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

